TMEM106B: a strong FTLD disease modifier. - Wikidata - awgldk - TriplyDB

TMEM106B: a strong FTLD disease modifier.

TMEM106B: a strong FTLD disease modifier.

http://www.wikidata.org/entity/Q42332631

about

Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study.Differential clinicopathologic and genetic features of late-onset amnestic dementias ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target.TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III.Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes.Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency Frontotemporal dementia: insights into the biological underpinnings of disease through gene co-expression network analysis "New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS).What we know about TMEM106B in neurodegeneration.Weighted Protein Interaction Network Analysis of Frontotemporal Dementia.Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity.TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins.

P2860

Q33729886-41E7A724-FE1B-4673-BEF5-E1519249996E Q35545502-87E4103C-8355-44B4-B771-6F3FB0F24F6E Q36322637-2F8BB62D-E9E3-4476-B914-4116CE9064EC Q36364206-5A664F2F-C24C-45B1-81FD-742F0C9E034C Q37530270-39A4420E-54E9-4D89-84E2-6558DD26ECFB Q37609848-47ABD396-3B41-41B8-B026-5A08C6CD2C68 Q38611043-FAE0083D-8FE5-4E95-8FCC-E7C0241AFB96 Q38841003-5739DCBA-3F6A-4400-9EA7-79F7D56D6EA1 Q38932474-655E2889-77A8-4CC0-B396-A9592D2E70FE Q39075742-B2CC3C7B-3335-4D38-8747-D57E69332728 Q55209391-C5BC466F-EB66-4C1D-9B88-C138197C20F3 Q55724715-7E1F77A9-024C-4281-BD13-E0DEBC9023EB

P2860

TMEM106B: a strong FTLD disease modifier.

http://www.wikidata.org/entity/Q42332631

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

TMEM106B: a strong FTLD disease modifier.

@en

TMEM106B: a strong FTLD disease modifier.

@nl

type

label

TMEM106B: a strong FTLD disease modifier.

@en

TMEM106B: a strong FTLD disease modifier.

@nl

prefLabel

TMEM106B: a strong FTLD disease modifier.

@en

TMEM106B: a strong FTLD disease modifier.

@nl

P1433

Q42332631-1D753650-1228-4A4A-9082-DC058DBF1154

P1476

Q42332631-593FC37E-9223-41A1-925F-842ADD964F27

P2860

Q42332631-11DE35DC-440F-4A73-90EF-C3C37C594BF4

Q42332631-1CACEE34-C4E7-497F-8D9A-8B4B456230AD

Q42332631-237481B1-7882-479D-A5DB-227B8189F274

Q42332631-29C41EC1-144E-4112-BE12-79403E63226E

Q42332631-388C0EA5-8002-4C6A-BA95-D6047CB9CB7A

Q42332631-4B792DAC-365D-461A-9FAA-E42C3DA997CD

Q42332631-4BB3D409-FA38-4BFB-90F2-ADC2B3A2063F

Q42332631-78BBB85F-E010-40FC-8B4E-0691C2AC9DF2

Q42332631-7B0E12C4-1135-4250-9611-57F16F33D971

Q42332631-7E92A090-4660-426A-9B61-A441B15128F0

P2888

Q42332631-7C705CC2-A079-44BC-A9D4-E7D7609756CD

P304

Q42332631-6A1D957C-EB42-451C-A584-055EF6A9ED58

P31

Q42332631-DECBECB1-FB4B-48BD-9F75-8B3A4ED687F5

P356

Q42332631-45A7FAE7-A582-4E88-BD1E-CC9547A8F3F4

P433

Q42332631-91658F2C-5597-4683-9974-8352B6820FDD

P478

Q42332631-57E04962-DB1E-42D7-A5C2-C5A24CF9FC1D

P50

Q42332631-934FF19C-0A97-4036-8691-DFD1BE21F842

Q42332631-98AC6A0E-A352-4A3C-A6D7-2A585D0F37C8

P577

Q42332631-18E04567-8708-4202-A481-6E4CF6609A7A

P698

Q42332631-6038EE4D-2EFA-46DF-B808-C9B838AF3B0D

P932

Q42332631-34D089AA-156E-4679-A309-BD4D8524AC73

P356

S00401-014-1249-3

P1433

Acta Neuropathologica

P1476

TMEM106B: a strong FTLD disease modifier.

@en

P2860

Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.

TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers.

Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.

Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis.

TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways.

P2888

s00401-014-1249-3

P304

419-422

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00401-014-1249-3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

Carlos Cruchaga

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24488309

http://www.w3.org/2001/XMLSchema#string

P932

5494845

http://www.w3.org/2001/XMLSchema#string